Publications en collaboration avec des chercheurs de Eli Lilly and Company (19)

2023

  1. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90

2022

  1. Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients with High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy - Reply

    JAMA Oncology

  2. Treatment with Adjuvant Abemaciclib Plus Endocrine Therapy in Patients with High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial

    JAMA Oncology, Vol. 8, Núm. 8, pp. 1190-1194

  3. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64

2021

  1. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

    npj Breast Cancer, Vol. 7, Núm. 1

  2. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  3. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

    Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2

2020

  1. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

    Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998

  2. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer

    Future Oncology, Vol. 16, Núm. 33, pp. 2763-2778

  3. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

    Oncologist, Vol. 25, Núm. 9, pp. e1346-e1354

  4. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in Neomonarch, phase II neoadjuvant study in HR+/HER2- Breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 3, pp. 566-580

2019

  1. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials

    European Journal of Cancer, Vol. 117, pp. 91-98

  2. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

2018

  1. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

    npj Breast Cancer, Vol. 4, Núm. 1

2015

  1. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

    Journal of Clinical Oncology, Vol. 33, Núm. 2, pp. 141-148

2013

  1. A randomized phase II non-comparative study of pemetrexed carboplatin and gemcitabine vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients

    International Journal of Oncology, Vol. 42, Núm. 5, pp. 1778-1785

2009

  1. A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer

    Clinical Breast Cancer, Vol. 9, Núm. 3, pp. 155-160

  2. TRIO-012: A multicenter, multinational, randomized, double-blind phase iii study of imc-1121b plus docetaxel versus placebo plus docetaxel in previously untreated patients with her2-negative, unresectable, locally recurrent or metastatic breast cancer

    Clinical Breast Cancer, Vol. 9, Núm. 4, pp. 258-261

2007

  1. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer

    Clinical Cancer Research, Vol. 13, Núm. 12, pp. 3652-3659